Corcept Therapeutics is trading at $80.44, down 6.49%, with no verified company-specific announcement identified to explain the decline.
- Corcept’s investor-relations page lists its latest releases as October 27 and earlier.
- A report linked drug-pricing scrutiny to pharma-share declines and said biotech stocks fell around 1.5%; it did not identify Corcept as affected.
- This sector backdrop is context, not a confirmed explanation for Corcept’s larger move; Q3 results are scheduled for November 3.